Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas

Head and Neck

Volumn 34, Issue 5, 2012, Pages 626-631

  Giovanella, Luca ^a   Ceriani, Luca ^a   De Palma, Diego ^b   Suriano, Sergio ^a   Castellani, Massimo ^c   Verburg, Frederik A ^d  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b OSPEDALE DI CIRCOLO   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

18F fluorodeoxyglucose, radioiodine; differentiated thyroid carcinoma; positron emission tomography; thyroglobulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIATED THYROID CANCER; FEMALE; FOLLOW UP; HUMAN; IMAGE RECONSTRUCTION; IODINE 131 UPTAKE TEST; MALE; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; WHOLE BODY PET; X RAY;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; YOUNG ADULT;

EID: 82955174482     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21791     Document Type: Article

References (25)

1. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
2. Fatourechi V, Hay ID,. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive and iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med 2000; 30: 107-114.
3. Frilling A, Görges R, Tecklenborg K, et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000; 128: 1067-1074.
4. Grünwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996; 23: 312-319.
5. Freudenberg LS, Frilling A, Kühl H, et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol 2007; 17: 3139-3147.
6. Mirallié E, Guillan T, Bridji B, et al. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery 2007; 142: 952-957; discussion 958.
7. Shammas A, Degirmenci B, Mountz JM, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007; 48: 221-226.
8. Iagaru A, Kalinyak JE, McDougall IR,. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 2007; 32: 690-695.
9. Miller ME, Chen Q, Elashoff D, Abemayor E, St John M,. Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck [Epub ahead of print].
10. Menzel C, Zaplatnikov K, Diehl M, Döbert N, Hamscho N, Grünwald F,. The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl Med Commun 2004; 25: 239-243.
11. Lebolleaux S, Schroeder PR, Schlumberger M, Ladenson PW,. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 2007; 3: 112-121.
12. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
13. Bertagna F, Bosio G, Biasiotto G, et al. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med 2009; 34: 756-761.
14. Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M,. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001; 42: 71-76.
15. Grünwald F, Kälicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26: 1547-1552.
16. Stokkel MP, Duchateau CS, Dragoiescu C,. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 2006; 50: 78-87.
17. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84: 2291-2302.
18. Nahas Z, Goldenberg D, Fakhry C, at al,. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005; 115: 237-243.
19. American Joint Committee on Cancer: Chapter 8: Thyroid, in AJCC cancer staging handbook. 6th ed. Springer, New York, 2002. pp 89-98.
20. Giovanella L,. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med 2008; 46: 1067-1073.
21. Leboulleux S, Schroeder PR, Busaidy NL, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009; 94: 1310-1316.
22. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H,. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24: 1342-1348.
23. Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M,. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001; 42: 71-76.
24. Vera P, Kuhn-Lansoy C, Edet-Sanson A, et al. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D- glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Thyroid 2010; 20: 15-23.
25. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85: 1107-1113.